LYEL Lyell Pharma Company Short-Term Debt

Lyell Immunopharma, Inc. - graphic logo of issuer LYEL

Lyell Immunopharma (LYEL) develops innovative methods for combating tumors by stimulating the body's own defenses, while the individual debt metric stands at 0.01. The market trend for the asset shown on this price chart confirms the current momentum. The drug development process is accelerating through automation and digital molecular modeling. Since the company is focused on trials, its capitalization depends on scientific breakthroughs rather than market pricing.

LYEL lyell.com Short-Term Debt (07/04/2022 - 11/01/2026)

Analytical breakdowns and data insights for company Lyell Pharma (LYEL)

- current quotes and average value forecast:
Price Chart Lyell Immunopharma, Inc.|LYEL - Average Forecast Price
- market capitalization data:
Market Value Lyell Immunopharma, Inc.|LYEL - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Lyell Immunopharma|LYEL - Total Stockholders' Equity|Market Capitalization to Book Value Ratio lyell.com|LYEL - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Lyell Immunopharma|LYEL - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Lyell Immunopharma|LYEL - Aggregate Debt Obligations|Debts to Book Capitalization Lyell Immunopharma, Inc.|LYEL - Long-Term Debt Volume|Company Short-Term Debt Lyell Immunopharma|Quick Liquidity lyell.com
- earnings and multiples data:
LYEL - Net Income
General company analysis:Lyell Immunopharma, Inc. (LYEL)
Flagship merchandise of lyell.com

Short-term debt measures the total liabilities with a maturity of up to one year. This current debt obligations chart reflects immediate liquidity and the company's ability to service loans. An increase in this metric signals rising financial risks during market volatility. For Lyell Immunopharma (LYEL), a low debt load is critical when financing multi-stage T-cell research. This ensures the stability of the pipeline during the testing of drugs against solid tumors.

Competitors of Lyell Immunopharma

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt Zymeworks Inc.|Short-Term Debt tangotx.com TNGX|Company Short-Term Debts IOVA|Immatics NV (IMTX) - Short-Term Indebtedness|Xencor Corp - Company Current Liabilities|Compass Therapeutics Corp (CMPX) - Short-Term Debt|REPL: Company Current Liabilities|Company Short-Term Loans and Borrowings IPHA (innate-pharma.com)|PYXS: Company Short-Term Debts|CGEN - Short-Term Debt Volume|Company Short-Term Debt IO Biotech Corp|Company Current Liabilities Sutro Biopharma, Inc (STRO)|Company Short-Term Debt MiNK Therapeutics, Inc. (INKT)|Company Current Liabilities werewolftx.com HOWL|Immix Biopharma - Company Current Liabilities|Company Short-Term Debts alxoncology.com ALXO|CUE - Company Short-Term Debt|PDSB (PDS Biotechnology) - Company Short-Term Indebtedness|sonnetbio.com (SONN) - Company Short-Term Debt|Short-Term Debt MAIABiotech.com (MAIA)|Company Current Liabilities LIMN|LVTX - Short-Term Indebtedness|Company Current Liabilities NXTC (NextCure Corp)|Amount of Current Liabilities LPTX|Company Short-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Short-Term Loans and Borrowings SNSE|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)